ADVERTISEMENT
ADVERTISEMENT

Right on Geron

The US Food and Drug Administration's linkurl:decision;http://www.the-scientist.com/blog/display/55353/ to green light a human embryonic stem cell-based therapy for spinal cord injury isn't just good news for the biotech in question, Geron Corp., analysts say -- instead, they argue, the move opens the door to an entire market that has heretofore been stymied. "It's the first clear evidence of the FDA's willingness to permit cells derived from pluripotent stem cells to go into human trials," lin

Elie Dolgin
The US Food and Drug Administration's linkurl:decision;http://www.the-scientist.com/blog/display/55353/ to green light a human embryonic stem cell-based therapy for spinal cord injury isn't just good news for the biotech in question, Geron Corp., analysts say -- instead, they argue, the move opens the door to an entire market that has heretofore been stymied. "It's the first clear evidence of the FDA's willingness to permit cells derived from pluripotent stem cells to go into human trials," linkurl:Kenneth Aldrich,;http://people.forbes.com/profile/kenneth-c-aldrich/44832 CEO of Oceanside, Calif.-based linkurl:International Stem Cell Corporation,;http://www.internationalstemcell.com/ told __The Scientist__. "It'll make it easier for us and everyone else, because we now have a roadmap. We know what the FDA wants." "What this essentially says is that the FDA is comfortable with trials involving human embryonic stem cells," said linkurl:Robert Lanza,;http://www.robertlanza.com/ chief scientific officer of Advanced Cell Technology (ACT), a biotech company in Cambridge, Mass. "Now, others moving forward don't have as high a...

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
ADVERTISEMENT